On July 20, DotBio-B rose 7.07% in regular trading, trading at HK$231.4 per share, with turnover of HK$122 million.

On the news front, the company recently presented initial Phase I/IIa results for DB-1310 in advanced solid tumor patients via an oral presentation at the ASCO annual meeting. DB-1310 had previously established a collaboration with AstraZeneca to explore combination therapy with osimertinib. Concurrently, partner Avenzo announced on July 16 its Nasdaq listing through a reverse merger, completing a US$215 million oversubscribed PIPE financing. A core asset of Avenzo is the EGFR/HER3 bispecific ADC DB-1418 licensed from DotBio, further validating the commercial value of the company's pipeline.

Within the Biotechnology sector, the overall sector showed broad strength. Among individual stocks, Remegen up 7.28%, Akeso up 5.83%, 3SBio up 4.77%, Innovent Bio up 3.88%, BeiGene up 3.39%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)